Mainstay Medical

Mainstay Medical is a commercial-stage medical device company with a mission to transform the treatment of chronic low back pain through its proprietary Restorative Neurostimulation™ platform. Its core achievement is the development and regulatory approval of the ReActiv8® system, which received FDA De Novo clearance in 2021 and CE Mark in 2016, establishing a new therapeutic category. The company's strategy is built on generating robust, long-term clinical evidence to drive physician adoption and secure reimbursement, targeting a vast and underserved patient population. Mainstay is now focused on scaling commercial operations in the US and Europe to capture this significant market opportunity.

Restorative Neurostimulation™ platform, an implantable system that delivers electrical pulses to re-activate and rehabilitate the multifidus muscle to treat chronic low back pain.